← boardnext 2026-08
RGNX
REGENXBIO Inc.distress 7/10 · high distress / dilution risk$9.82-4%today-39% from 52w high
Lead: Duchenne muscular dystrophy · est. market ~$4B (approx, global)
Revenue
pre-revenue
Liquidity
$161M
Runway
0.7 yrs
Shares 1y
+2%
Price & events
-38.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.7%
1D
-12.3%
1W
-1.3%
1M
+9.3%
3M
-28.8%
6M
+8.1%
1Y
-27.2%
2Y
-71.9%
5Y
-78.2%
All
Overview
- Market Cap
- $507.93M
- Volume
- 128.56K
- 52 Week Range
- $5.65 – $15.98
- Total Shares
- 51.70M
- Float Shares
- 43.04M
- Short %
- 21.77%
- % Held by Insiders
- 8.06%
- % Held by Institutions
- 81.93%
- RVOL
- 0.05x
- Beta
- 0.90
Pipeline stages · 1 programs
RGX-121-3102
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 2/3 | RGX-202priority revieworphanrare pediatricfast trackrmat | Duchenne Muscular Dystrophy | — | recruiting |
| 2028-04-30 Estimated 50% readout ~2028-07-14 | Phase 3 | RGX-121-3102priority revieworphanrare pediatricfast trackrmat | MPS II, Hunter Syndrome (MPS II) | — | active not recruiting |
Catalyst news & presentations · 22
- Q4 2026Guided 70%readoutPhase 3sura-vec · Topline data from ATMOSPHERE and ASCENT pivotal trials of sura-vec using subretinal delivery.SEC 8-K
- Q4 2026Guided 70%readoutPhase 3sura-vec (ABBV-RGX-314) · Topline pivotal data from ATMOSPHERE and ASCENT trials of subretinal delivery.SEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)RGX-202 · BLA submission planned using accelerated approval pathwaySEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- July 2026Estimated 45%conferencedata presentationsecondaryPhase 2sura-vec · Presentation of two and a half-year data from long-term follow-up of ALTITUDE trial at ASRS 44th Annual Meeting.SEC 8-K
- mid-yearenrollment completesecondaryPhase 3RGX-202 · Expected completion of dosing in all 60 patients across pivotal and confirmatory trials.SEC 8-K
- mid-2026regulatory submissionFiled (NDA/BLA)RGX-202 · BLA submissionSEC 8-K
- first half of 2026readoutRGX-202 · topline dataSEC 8-K
- Q2 2026trial initiationsecondaryPhase 2sura-vec · First patient dosed in Phase IIb/III NAAVIGATE study.SEC 8-K
- 2026-06-29partnershipsura-vec · Earned $100 million milestone from AbbVie for first patient dosed in Phase IIb/III trial for diabetic retinopathy.SEC 8-K
- February 8, 2026PDUFAPDUFAclemidsogene lanparvovec (RGX-121) · Extended PDUFA action date for BLA seeking accelerated approvalSEC 8-K
- 2026-02-07crlRGX-121 · FDA issued Complete Response Letter for RGX-121 BLA for MPS IISEC 8-K
- 2026-01-28clinical holdRGX-121 · FDA placed clinical hold on Phase I/II/III trial of RGX-121 for MPS II due to similarities with RGX-111 programSEC 8-K
- 2025-11-09PDUFAPDUFARGX-121 · Potential FDA approval as early as late 2025SEC 8-K
- by October 2025enrollment completesecondaryRGX-202SEC 8-K
- September 2025conferencedata presentationsecondaryclemidsogene lanparvovec (RGX-121) · Present updated pivotal data at ICIEM meetingSEC 8-K
- 2025-08-18pdufa extensionclemidsogene lanparvovec (RGX-121) · FDA extended PDUFA date from November 9, 2025 to February 8, 2026 for RGX-121 BLA reviewSEC 8-K
- 2025-08-05partnershipABBV-RGX-314 · Amendment with AbbVie modifies DR and wAMD programs, includes new milestone paymentsSEC 8-K
- 2025-05-16partnershipRoyalty monetization agreement with HCRx for up to $250 million.SEC 8-K
- 2025-03-04partnershipClosed collaboration and license agreement with Nippon Shinyaku for development and commercialization of RGX-121 and RGX-111 in the US and Asia.SEC 8-K
- 2025-01-14partnershipRGX-111 · Collaboration and License Agreement with Nippon Shinyaku for development and commercializationSEC 8-K
- November 18, 2024trial initiationsecondaryPhase 3RGX-202 · Initiated pivotal phase of AFFINITY DUCHENNE trial and dosed first patientSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $24 (+147% upside) · 11 analysts
- 2026-06-24HC Wainwright & Co.Buy
- 2026-06-22BairdOutperform
- 2026-06-22Leerink PartnersOutperform
- 2026-06-05HC Wainwright & Co.Buy
- 2026-05-15B of A SecuritiesBuy
- 2026-05-15BarclaysOverweight
Competitors — Duchenne muscular dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
- SLDBSolid Biosciences Inc.$777M · D4
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- PEPGPepGen Inc.$133M · D6
- CPIXCUMBERLAND PHARMACEUTICALS INC$102M · D0
Recent news
- 2026-07-22RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
- 2026-07-21Lawsuit alleges Regenxbio misled investors on g... - Pluang
- 2026-07-21Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm - Morningstar
- 2026-07-20Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Benzinga
- 2026-07-20RegenXBio Raises Capital Through Public Equity Offering - TipRanks
- 2026-07-20Regenxbio (RGNX) Reports Positive Long-Term Results for Gene The - GuruFocus
- 2026-07-18Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting - Bitget
- 2026-07-18REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.